Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

New treatment discovered for heart tissue scarring after infarct

Jan. 9, 2020

Cytokinetics initiates phase II trial of CK-3773274 for hypertrophic cardiomyopathy

Jan. 7, 2020

Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation

Dec. 31, 2019

Quantum Genomics begins phase III study of firibastat in hypertension

Dec. 23, 2019

FDA approves IND for phase I trial of TransThera's TT-00920 for heart failure

Dec. 18, 2019

FDA approves Vascepa to reduce cardiovascular risk in adults with elevated triglyceride levels

Dec. 16, 2019

Sunshine Lake Pharma discloses mineralocorticoid receptor antagonists

Dec. 9, 2019

Development of preclinical canine models for pharmacological studies of AF

Dec. 5, 2019

Kancera presents data from in-depth analysis of KAN-D567 phase Ib program

Dec. 5, 2019

First patient dosed in phase II study of zilucoplan for the treatment of IMNM

Dec. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...